AC
ALXN

Ascend Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Ascend Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-39,210
Closed -$5.5M – 265
2017
Q3 		$5.5M Buy
+39,210
New +$5.33M 0.21% 105
2017
Q2 		– Sell
-123,755
Closed -$15M – 198
2017
Q1 		$15M Buy
+123,755
New +$16M 0.68% 54
2016
Q3 		– Sell
-209,011
Closed -$24.4M – 176
2016
Q2 		$24.4M Buy
+209,011
New +$29.7M 1.6% 15
2016
Q1 		– Sell
-11,636
Closed -$2.22M – 163
2015
Q4 		$2.22M Sell
11,636
-13,738
-54% -$2.4M 0.08% 128
2015
Q3 		$3.97M Sell
25,374
-145,322
-85% -$26.5M 0.16% 97
2015
Q2 		$30.9M Buy
170,696
+29,962
+21% +$5.17M 1.02% 34
2015
Q1 		$24.4M Buy
+140,734
New +$25.5M 0.84% 40

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ascend Capital's ALXN Position: Q4 2017 in Review

Ascend Capital sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 39,210 shares — an estimated $5.5M sold.

Ascend Capital first reported a position in ALXN in Q1 2015 and held it in 7 quarters. The position peaked at $30.9M in Q2 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Ascend Capital reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Ascend Capital sold 39,210 Alexion Pharmaceuticals shares in Q4 2017, an estimated $5.5M.
  • Ascend Capital first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 7 quarters.
  • Ascend Capital's Alexion Pharmaceuticals position peaked at $30.9M in Q2 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.